Priority Date: 19.06.12 (GB 20120010857)

TRANSCRIPTION FACTOR MEDIATED PROGRAMMING TOWARDS MEGAKARYOCYTES

  • Application ID: EP13734473
  • Status: EXAMINATION IN PROGRESS

Applicant

Company dna cambridge enterprise ltd
Technology Transfer Office

Attorney

operating since 1890
Headquarter in London and 4 offices
active in Legal Services

Specialization

This patent has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C12 (BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING) Mewburn Ellis LLP is specialized in the combination A61 and C12. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Sperling Fischer & Heyner, Zacco Denmark A/S, Lederer Keller Patentanwälte Partnerschaft mbB and 172 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 19.06.2012 - Priority Date (GB 20120010857)
  • 27.12.2013 - Publication A1 (WO2013190296)
  • 22.04.2015 - Publication A1 (EP2861724)

IPC Classification